Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007373:Interinstitutional Relations; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D010770:Phosphotransferases / Q000037:antagonists & inhibitors*; D012106:Research / Q000191:economics* / Q000458:organization & administration
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D010770:Phosphotransferases